Clinical trials: Type Two Diabetes Mellitus
Type 1 Diabetes Mellitus
Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)
Primary Objective: To evaluate the effect of virtual approach via novel technologies versus traditional study conduct on glycemic control in terms of glycated hemoglobin (HbA1c).
- Trial name
- NCT03260868
- Testing
- Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
- Where
- 6 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®
To compare efficacy and safety of Exubera® vs Lantus® in patients with type 2 diabetes mellitus.
- Trial name
- NCT00391027
- Testing
- Insulin Glargine (Lantus®), Inhaled Human Insulin (Exubera®)
- Where
- 62 sites in Belgium, Finland and 8 more
- Volunteers
- 261 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes
The purpose of this clinical trial is to test safety and tolerability of a vaccine targeting Interleukin-1 beta in patients with type 2 diabetes.
- Trial name
- NCT00924105
- Testing
- CYT013-IL1bQb
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 48 people
- Sponsor
- Cytos Biotechnology AG
Diabetes Mellitus, Type 2
Insulin Glargine Combination Therapies in Type II Diabetics
To compare efficacy of combination therapy of insulin glargine plus glimepiride and metformin versus 2 injections insulin monotherapy with premixed insulin NPH 30/70 bid in terms of change of HbA1c (baseline to endpoint) to show…
- Trial name
- LAPTOP (NCT00783744)
- Testing
- Insulin Glargine, Glimepiride, Metformin
- Where
- 10 sites in Austria, Finland and 8 more
- Volunteers
- 375 people
- Sponsor
- Sanofi
Type II Diabetes
Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy Adults
Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability after Oral Administration of CKD-387 10/1000 mg and D484 10/1000mg in Healthy Adults
- Trial name
- NCT03646799
- Testing
- CKD-387, D484
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension, Type II Diabetes Mellitus
Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria
This is a phase II a, double-blind, randomized, parallel-design, four-week study to investigate the efficacy, safety and tolerability of two different doses of SPP635 in type II diabetic patients with mild to moderate…
- Trial name
- NCT00561171
- Testing
- SPP635
- Where
- Ireland
- Volunteers
- 50 people
- Sponsor
- Speedel Pharma Ltd.
Diabetes Mellitus, Type 2
A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes.
- Trial name
- NCT03922750
- Testing
- Insulin icodec, Insulin glargine U100
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 154 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00039013
- Testing
- AC2993
- Where
- 129 sites in United States
- Volunteers
- 336 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate pharmacokinetics, pharmacodynamics and safety of biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- NCT01697618
- Testing
- biphasic insulin aspart 30, biphasic human insulin 30
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Novo Nordisk A/S
Xerosis Cutis
Comparison Dry Foot Skin Between Diabetic and Non-diabetic Subjects and the Effects of Two Cosmetic Foot Care Products
The overall aims of this study are to compare the structure and function of dry to very dry and cracked foot skin between diabetic and nondiabetic subjects and to evaluate the effects of two cosmetic leave-on products on dry and…
- Trial name
- NCT05046015
- Testing
- 10% Urea foot lotion, 10% Urea foot ointment
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Galderma R&D
Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fed Conditions
The purpose of this clinical study is to evaluate the pharmacokinetics and safety of BR3409 and co-administration of BR3409-1 and BR3409-2 in healthy volunteers Under Fed Conditions
- Trial name
- NCT06879132
- Testing
- BR3409, BR3409-1, BR3409-2
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes
Glycemic Response to Oral Nutrition Supplements
This will be a randomized, cross-over study of two oral nutrition supplements in individuals with Type 2 Diabetes.
- Trial name
- NCT02612675
- Testing
- ONS
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Société des Produits Nestlé (SPN)
Bioequivalence, Diabetes Mellitus, Type 2
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose…
- Trial name
- NCT06124495
- Testing
- Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet
- Where
- Mexico
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.
- Trial name
- ONWARDS 1 (NCT04460885)
- Testing
- Insulin icodec, Insulin glargine
- Where
- 198 sites in United States, Croatia and 11 more
- Volunteers
- 984 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy
Primary Outcomes: Average decrease in A1c from baseline to end of Study Phase (52 weeks) for subjects in the "722 Group" is greater than that for subjects in the "Control (MDI) Group".
- Trial name
- STAR3 (NCT00417989)
- Testing
- MiniMed Paradigm REAL-Time System
- Where
- 30 sites in United States, Canada
- Volunteers
- 485 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Non-Insulin-Dependent
Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus
This is a multicenter, randomized, blinded, placebo-controlled, short-term, dose-response study to examine the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00044694
- Testing
- AC2993 2.5 mcg
- Where
- 33 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension
This study is designed to evaluate the pharmacokinetics, tolerability, and safety of exenatide once weekly suspension in both healthy subjects and in subjects with type 2 diabetes.
- Trial name
- NCT00894322
- Testing
- exenatide once weekly
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes
The primary purpose of this study is to compare the effect of a double dose of a study drug known as insulin peglispro to a double dose of insulin glargine in participants who have type 2 diabetes.
- Trial name
- IMAGINE 8 (NCT02132637)
- Testing
- Insulin Peglispro, Insulin Glargine
- Where
- 3 sites in United States, Germany
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
AT278 and NovoRapid® in Glucose Clamp Study
A phase 1, randomised, single-centre, double-blind, single-dose, two period balanced cross over study in a glucose clamp setting.
- Trial name
- NCT04660305
- Testing
- AT278, NovoRapid
- Where
- Austria
- Volunteers
- 38 people
- Sponsor
- Arecor Limited
Diabetes, Diabetes Mellitus, Type 2
A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability and bioavailability (exploring absorption of drug in body) of NN9925 in healthy male subjects.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01087645
- Testing
- NN9925 (oral), NN9925 (i.v.)
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S